Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.
| MAIN OUTCOME ME A SURE S
The main outcome measures were survey questions on the frequency of advanced planning of sexual intercourse, timing of PDE5I ingestion, the frequency of sexual intercourse per month and the frequency of ED medication use per month. Descriptive results are reported. Table 1 ). The percentages of respondents according to age subgroups for the total population and for each individual country are shown in Table 1 . The largest age subgroup in 6 of the 7 countries was 41-50 years; in Japan, 51-60 years was the largest age subgroup. In the total population of 1458 men, 36% self-reported the presence of high blood pressure, 30% reported high cholesterol, 26% reported prostate problems, 22% reported depression and 19% reported diabetes. Comorbidities reported by age subgroup are shown in Table 2 . The ED medications respondents reported taking (screening questions) included generic and branded sildenafil citrate, generic and branded tadalafil and branded vardenafil. Medication selection was based on the options available in each country at the time of the survey. Overall, 35% reported that the PDE5I last used was sildenafil (branded); 28% reported tadalafil (branded), and the remainder was distributed among the other agents used. Most participants (51%) had used only 1 type of PDE5I in the previous 3 months; 28% had used 2 and 15% had used 3 PDE5Is. Six per cent had used ≥4 PDE5I agents. These values were similar by age subgroup, with the exception that 10% of respondents aged 30-40 years reported taking ≥4 PDE5Is in the previous 3 months (Table 2) .
| RE SULTS

| Respondents
Overall
What's known
• Patient satisfaction with erectile dysfunction treatment could be optimised by using an oral phosphodiesterase type 5 inhibitor (PDE5I) with attributes that best suit a patient's sexual habits.
• Little is known regarding the sexual habits and behaviours of men taking PDE5Is.
What's new
• This 7-country survey demonstrated that men taking a PDE5I typically plan sexual activity several hours in advance.
• Despite their planning efforts, most PDE5I users attempted sexual activity within a short time after ingestion of the agent.
| Sexual habits survey
Of the 1458 men who reported taking ED medication, 83% reported that they always or sometimes planned for sexual intercourse in advance ( Figure 1 ). There was reasonable concordance in this regard among countries, although these rates varied from 73% in Japan to 95% in China. Similarly, most respondents in any age subgroup reported always or sometimes planning intercourse in advance (Table 2) .
Of those planning sexual activity in advance, 72% planned sexual intercourse up to several hours in advance (Figure 2 ).
There was significant variability in this factor among countries, with planning up to several hours in advance reported by 39% of respondents from Japan and 81% in Russia, with Japan being the only country where a notable proportion of respondents planned more than 1 week in advance. Furthermore, of the respondents who indicated that they planned in advance, many planned specific days of the week (55%) and times of the day (60%) for sexual intercourse ( Figure 3 ). Among age subgroups, nearly half of those aged 30-60 years planned sexual intercourse up to several hours in advance, whereas 39% of those aged 61-70 years did so. Similar to the total population, most respondents reported planning for specific days of the week and times of the day (Table 2 ).
Thirty per cent of ED medication users strongly agreed with the statement, "I plan when I am going to have sexual intercourse." Among men using generic or branded tadalafil, branded vardenafil or generic sildenafil, no statistically significant differences were observed for percentages that strongly agreed with this statement (mean, 30%). Only 2%-3% of men strongly disagreed with the statement, no matter which PDE5I was last used.
In the total population of 1458 men, the time to sexual activity commencement after ED medication dosing was ≤30 minutes for 20%, 30-60 minutes for 50% and 1-4 hours for 26%, with Only 22% of respondents reported being very satisfied with the ED medication that they had last used, and 63% were fairly satisfied; similar percentages were reported by age subgroup (17%-24% very satisfied, 59%-64% fairly satisfied). 9 (4) 3 (1) 8 (8) 11 (4) 7 (3) 27 (11) 13 (13) 41-50 y 787 (54) 110 (44) 165 (65) 64 (64) 138 (55) 83 (33) 157 (63) 70 (70) 51-60 y 446 (31)
TA B L E 1 Age and comorbidities of survey respondents
86 (34) 81 (32) 23 (23) 77 (31) 102 (41) 62 (25) 15 (15) 61-70 y 147 (10) 47 (19) 5 (2) 5 (5) 25 (10) 58 (23) 5 (2) 2 (2) Comorbidities, n (%)
High blood pressure
(36)
90 (36) 67 (26) 63 (63) 97 (39) 60 (24) 116 (46) 30 (30) High cholesterol 432 (30) 87 (35) 53 (21) 48 (48) 100 (40) 52 (21) 67 (27) 25 (25) Prostate problems
(26)
47 (19) 110 (43) 25 (25) 78 (31) 32 (13) 76 (30) 18 (18) Depression
(22)
63 (25) 26 (10) 17 (17) 59 (24) 30 (12) 85 (34)
(39)
Diabetes 276 (19) 66 (26) 47 (19) 30 (30) 44 (18) 35 (14) 31 (12) 23 (23) TA B L E 2 Results by age subgroup Hardly ever 181 (12) 9 (12) 89 (11) 62 (14) 21 (14) Never 51 (3) 2 (3) 23 (3) 14 (3) 12 (8) Do not know
Prefer not to say
Timing of advanced planning of sexual intercourse, n (%) N = 1391 n = 76 n = 754 n = 429 n = 132 
| D ISCUSS I ON
The primary objective of the current study was to better understand the sexual habits, behaviours, and treatment satisfaction of men who 7 countries who reported taking a PDE5I in the past 3 months, the survey response rate (48%) was good and comparable to that of a recent internet-based survey of male sexuality. 11 For Russia and Brazil, lower age ranges were applied based on feedback from local opinion leaders that ED tends to emerge at a younger age in these countries. Patient comorbidity profiles were similar to those seen in the general ED population, [12] [13] [14] suggesting that the respondents were representative of this population and supporting extrapolation of these findings to most patients with ED.
The frequency of sexual intercourse reported for the overall population in the current survey (median: 6 times/month; range 4-8 times/month; mean: 7 times/month) is similar to that reported in previous studies. [15] [16] [17] [18] The reasons for differences among countries in this regard were not investigated but is a topic worthy of further exploration.
The key messages from the data are that the respondents often planned sexual activity in advance, with 83% planning in advance at least sometimes; the majority plan to have sex up to several hours in advance; and nearly all ED medication users were having sexual activity within 4 hours of ingesting their PDE5I. Thus, these data challenge the concept of spontaneity; the majority of people appear to be having sex in a highly planned fashion. In this regard, these planning data are in contrast to a study by Eardley et al, which showed in an internet survey that the median time frame from thinking about sex to having sexual activity was 30 and 31 minutes (mean time frame: 53 and 54 minutes) for men with ED and those without ED, respectively, with the time frame decreasing with increasing age.
19
This difference could be explained by cultural factors. The fact that nearly all men were having sex within 4 hours of using their PDE5I
is of clinical importance. Clinicians should now consider discussing sexual dynamics with patients to define their sexual patterns and Another interesting finding from this survey is the proportion of PDE5I users ingesting the medication within 30 minutes of sexual activity, which is in stark contrast to the labelling of the agents. This might reflect the failure of prescribing clinicians to advise patients how to use the medications correctly or may indicate that patients were receiving the medication through non-medical sources (it is not known whether participants were taking PDE5Is that were prescribed or purchased over the internet).
Of note, the PDE5Is used in this study included sildenafil (branded and generic), tadalafil (branded and generic, on demand and once a day) and vardenafil (branded). The major players were therefore included, but the study design excluded other agents used less frequently in the participating countries such as mirodenafil, lodenafil, avanafil and udenafil, although it is unlikely that patient use of these agents would have differed.
Limitations of the survey include the fact that some respondents (from Russia and Brazil) were younger than the general ED patient; the inability to confirm diagnosed ED (only the use of a 
| CON CLUS IONS
For the population assessed in this study, most ED medication users plan sexual intercourse ahead of the encounter, most up to several hours in advance, and nearly all take their PDE5I within a few hours of sexual activity. In clinical practice, a thorough understanding of patients' sexual habits, behaviours, and treatment goals can aid healthcare providers in the selection of the optimal ED medication for each patient. 
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